Maintaining muscle mass has proven to be crucial for patients undergoing cancer treatment. Studies have shown that ...

Camizestrant will reach blockbuster status in 2030 with total sales worth $1.1 billion, according to GlobalData’s analyst ...

MATHEMATICAL MODEL Biologist Regina Joyce Ferrer from the University of the Philippines analyzes breast cancer organoids.

A new triple-drug treatment for aggressive advanced breast cancer can cut deaths by a third, a major trial has found.

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

Increased consumption of olive oil may reduce the risk for specific subtypes of breast cancer, according to results of a prospective study.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase ...

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– ...

Thanks to artificial intelligence (AI), more women might soon benefit from targeted breast cancer treatment, a new study says ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical ...

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests.